LetterLetter
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?
Theodore Pincus, Martin J. Bergman and Yusuf Yazici
The Journal of Rheumatology October 2021, jrheum.210953; DOI: https://doi.org/10.3899/jrheum.210953
Theodore Pincus
Rush University Medical Center, Chicago, Illinois; Drexel University, College of Medicine, Philadelphia, Pennsylvania; NYU School of Medicine, New York, New York, USA. TP is president of Medical History Services LLC, which receives royalties and license fees from for-profit pharmaceutical companies and electronic medical record companies for use of MDHAQ and RAPID3. All license fees are used to support further development of quantitative measurement in clinical rheumatology care using patient and physician questionnaires. MJB receives speaking/consulting fees from AbbVie, Amgen, BMS, GSK, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi, and Scifer; and is a shareholder of Merck and Johnson & Johnson. YY receives research support from Amgen and BMS, and is a consultant for Amgen, BMS, and Sanofi. Address correspondence to Dr. T. Pincus, Rush University, 1611 West Harrison Street, Suite 510, Chicago, IL 60612, USA. Email: tedpincus@gmail.com.
Martin J. Bergman
Rush University Medical Center, Chicago, Illinois; Drexel University, College of Medicine, Philadelphia, Pennsylvania; NYU School of Medicine, New York, New York, USA. TP is president of Medical History Services LLC, which receives royalties and license fees from for-profit pharmaceutical companies and electronic medical record companies for use of MDHAQ and RAPID3. All license fees are used to support further development of quantitative measurement in clinical rheumatology care using patient and physician questionnaires. MJB receives speaking/consulting fees from AbbVie, Amgen, BMS, GSK, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi, and Scifer; and is a shareholder of Merck and Johnson & Johnson. YY receives research support from Amgen and BMS, and is a consultant for Amgen, BMS, and Sanofi. Address correspondence to Dr. T. Pincus, Rush University, 1611 West Harrison Street, Suite 510, Chicago, IL 60612, USA. Email: tedpincus@gmail.com.
Yusuf Yazici
Rush University Medical Center, Chicago, Illinois; Drexel University, College of Medicine, Philadelphia, Pennsylvania; NYU School of Medicine, New York, New York, USA. TP is president of Medical History Services LLC, which receives royalties and license fees from for-profit pharmaceutical companies and electronic medical record companies for use of MDHAQ and RAPID3. All license fees are used to support further development of quantitative measurement in clinical rheumatology care using patient and physician questionnaires. MJB receives speaking/consulting fees from AbbVie, Amgen, BMS, GSK, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi, and Scifer; and is a shareholder of Merck and Johnson & Johnson. YY receives research support from Amgen and BMS, and is a consultant for Amgen, BMS, and Sanofi. Address correspondence to Dr. T. Pincus, Rush University, 1611 West Harrison Street, Suite 510, Chicago, IL 60612, USA. Email: tedpincus@gmail.com.
Abstract
We agree strongly with Kremer et al that "metrics are essential for evaluating disease activity in patients with rheumatoid arthritis (RA)."1 Nonetheless, data reported from the Corrona and the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registries for Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) are quite similar to those reported in the initial 2008 RAPID3 report.2
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?
Theodore Pincus, Martin J. Bergman, Yusuf Yazici
The Journal of Rheumatology Oct 2021, jrheum.210953; DOI: 10.3899/jrheum.210953